






















4IDS/HIV Infection and Cerebrovascular Disease
mélia Nogueira Pinto, MD
The occurrence of cerebrovascular disease in patients with human immunodeficiency virus
(HIV) infection has been reported mainly in advanced stages of the disease and was
generally associated with nonbacterial thrombotic endocarditis, opportunistic infections, or
tumors, although in recent series a large number of cryptogenic strokes were found,
probably related to HIV vasculopathy. Recently a population-based study reported a strong
association between acquired immunodeficiency syndrome (AIDS) and both ischemic
stroke and intracerebral hemorrhage, with an incidence of 0.2% per year. However, with the
advent of highly active retroviral therapy (HAART)-causing immune restoration in HAART-
treated patients and avoiding early death and leading to a lengthening of the disease
free-survival, an older population was created, which is at higher risk for stroke. Further-
more, recent evidence suggests that accelerated atherosclerosis may be a potential risk for
stroke in these patients as it accompanies dyslipidemia and insulin resistance that were
found to be more frequent among patients in the HAART regimen. The relationship of HIV
infection and stroke is undergoing remarkable changes and epidemiological studies should
be performed on aging HIV populations to state the impact of this new information on the
incidence of cerebrovascular disease in HIV-infected patients and to identify factors that
are associated with its occurrence.
Semin Cerebrovasc Dis Stroke 5:40-46 © 2005 Elsevier Inc. All rights reserved.


















blthough neurological complications of human immuno-
deficiency virus (HIV) infection are common,1 the pres-
nce of cerebrovascular disease in HIV patients has been
eldom reported.2 The use of prophylaxis against opportu-
istic infections and the introduction of a new anti-retroviral
herapeutic regimen have led to reduced morbidity and mor-
ality in those patients infected with HIV.3 Furthermore, the
ntroduction of highly active retroviral therapy (HAART),
ith an immune restoration in HAART-treated patients, has
ed to a 50% decline in acquired immunodeficiency syn-
rome (AIDS) death rate, decreased maternal–fetal transmis-
ion rates, lower incidence rates of opportunistic infections,
nd a 40 to 50% decrease in the incidence of HIV-associated
ementia.4,5 This new reality probably will change the inci-
ence of strokes among AIDS patients, since stroke usually
ccurs in the later stages of the disease and is mainly due to
onbacterial thrombotic endocarditis, opportunistic infec-
ions, or neoplasm, although iatrogenic causes or associated
isk factors, such as intravenous drug abuse (IVDA), or a
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doi:10.1053/j.scds.2005.04.015irect relation to HIV itself due to an immunological and
etabolic response to HIV has been reported.2
This article will review available data on the association
etween stroke and AIDS/HIV infection based on published
linical and autopsy series, the mechanism of ischemic and
emorrhagic strokes in HIV-infected/AIDS patients, and the
mpact and risks of HAART regimen.
linical Series
everal reports are available on the association between HIV
nfection or AIDS and cerebrovascular events.2,6-29 Most of
hese reports describe cardioembolism, opportunistic infec-
ions, neoplasms, or inflammatory mechanisms to be the un-
erlying cause of stroke. In some cases, a possible event was
ttributed to a migraine aura,18 supposed to be induced by
he presence of anticardiolipin antibodies13,16 or caused by an
IV-associated vasculitis or vasculopathy.28 The reported
ate of stroke occurrence varies between 0.5 and 5% in dif-
erent clinical series.6-12,28,29
In a review by Pinto,2 a Medline research was performed
etween 1976 and 1994 and six clinical series were de-

















































































































AIDS/HIV infection and cerebrovascular disease 41ontrolled, and most of the series included predominantly
ases in “advanced stage of disease,” although staging was not
efined. A total of 1885 cases of AIDS, AIDS-related com-
lex, or patients with HIV infection was identified. Twenty-
ve patients (1.3%) had a stroke syndrome. Ischemic stroke
IS) was more common than intracerebral hemorrhage (ICH)
19 of 28 cases [68%] versus 9 of 28 cases [32%]). The
ajority of patients were homosexual men or patients with
istory of IVDA. Intracerebral hemorrhages were usually as-
ociated with thrombocytopenia, primary central nervous
ystem (CNS) lymphoma, or metastatic Kaposi sarcoma. ISs
ere generally due to nonbacterial thrombotic endocarditis
r concomitant opportunistic infections. Hematological con-
itions and cerebral vasculitis were reported in only a few
ases, although an unknown etiology was more frequent in a
ecent series of IS patients, with an HIV-related vasculitis
eing suggested.11,12,28 Due to limitations of the data, at that
ime it was not clear whether there was an association be-
ween AIDS and stroke.
Recently, Cole and coworkers29 reported a population-
ased study of AIDS-associated stroke, with an incidence of
oth IS and ICH in patients with AIDS of 0.2% per year. If
dentifiable causes for either disorders were excluded, the
ncidence of IS and ICH in AIDS patients was 0.14 and 0.11%
er year, respectively. The adjusted relative risk (RR) for both
S and ICH were significantly increased at 9.1 (95% confi-
ence intervals (CI), 3.4 to 24.6) for IS and 12.7 (95% CI, 4
o 40) for ICH, with a combined adjusted RR of 10.4. Only
IDS patients were included (according to the 1987 Center
or Disease Control (CDC) definitions of AIDS30), whereas
IV-positive patients (10 with IS and 5 with ICH) were in-
luded in the non-AIDS stroke group. Although underre-
orting of AIDS and stroke among the AIDS patients study
opulation was a potential confounder, it is unlikely that
hese or other confounders would have significantly changed
he authors’ results. Despite the absence of CD4 T-lympho-
ytes counts or other measures of immunological function,
he study population was collected before HAART regimen
as available, so all included patients had a profound immu-
osuppression. This population-based study found that
IDS is strongly associated with both IS and ICH. However,
ue to the small number of females, these results should not
e extended to them.
This association has been already suggested by some pre-
ious studies. Over a 5-year period, Engstrom and cowork-
rs,12 in a retrospective clinical series of 1600 AIDS patients,
ecorded 12 IS (0.75%) cases that were compared with the
nnual incidence of IS among young adults (aged 35 to 45
ears) and were higher than expected (0.0025%).31 Mocham
nd coworkers,27 in a prospective analysis of 35 hospital-
ased black South-Africans heterosexual HIV-infected pa-
ients, free of drug abuse and retroviral therapy, found 33
atients with IS and 2 with ICH, with a mean age of 32 years.
troke was the first manifestation of the disease in 20 patients
57%). Coagulopathy, predominantly due to protein S defi-
iency, was the principal etiology, followed by meningitis
nd cardioembolism. In two patients, a vasculitic process of
mall vessels, not associated with an opportunistic infection, oas found, and five patients had a cryptogenic stroke. A
istinction between HIV-infected patients and AIDS patients
as not found and respective stroke etiologies in each group
re unknown. Fourteen patients had AIDS on the basis of
D4 T-cells criteria (CD4 T cells200 mm3). Evers and
oworkers,28 in a prospective cohort study, conducted for 9
ears (1993 to 2001) on 772 consecutive HIV-infected pa-
ients, 639 of them younger than 46 years, found 15 patients
ith acute cerebrovascular disease, a prevalence rate of 1.9%.
ix patients had a transient ischemic attack (TIA) with a
revalence of 0.8% and nine had an IS, with a prevalence of
.2%. Ten of these patients were less than 46 years old with
rate of 1.6%, higher than reported for non-HIV patients.32
hen compared with the average annual incidence rate of TIA
r IS among the non-HIV population from the same region, the
IV clinical cohort ratewas about five times higher.33 IS patients
ere older, with lower CD4 T-lymphocytes counts, and in a
ore advanced stage of disease according to CDC classification.
n 10 patients no etiology was found and stroke was considered
ryptogenic. Dividing the cohort into two groups, with stroke
ccurring before and after 1997 when HAART regimen became
vailable, there was no difference in the incidence rate of stroke,
et the number of patients was small. Some bias and confound-
rs couldbe found in thepresent study, such as an increased rate
f focal neurological symptoms among the cohort patients, un-
erreporting of TIA, not all patients were fully investigated, and
igraine aura or focal seizures could had been confused with
IA. Nevertheless there was an increased rate of ischemic vas-
ular events in HIV-infected patients and in some cases an HIV-
ssociated vasculitis or vasculopathy was assumed to be the
nderlying etiology of the event.
In two retrospective case-control studies, an association
etween HIV infection and stroke was not established.21,25
ureshi and coworkers21 evaluated the relationship between
IV infection and stroke in young patients less than 45 ad-
itted between 1990 and 1994. They analyzed 236 stroke
atients, 113 with a known HIV status, 85% of them being
frican Americans, of whom 25 were HIV-positive (10 with
IDS). HIV-tested patients were more likely to be younger,
ocaine users, with an IS, and had less arterial hypertension;
IV-untested patients were more likely to die during hospi-
alization. When compared with age- and sex-matched con-
rols admitted due to status asthmaticus with known HIV
erology, and after adjusting for other known cerebrovascu-
ar risk factors, there was an increased risk of stroke among
IV-infected patients (odds ratio (OR) 2.3; 95% CI, 1.0 to
.3; P 0.05), particularly with IS (OR 3.4; 95%CI, 1.1 to
.9; P 0.03). However, after excluding patients with IS due
o meningitis or protein S deficiency (11 cases), the associa-
ion between HIV infection and IS was not statistically signif-
cant, suggesting that the excessive risk could be due to these
wo underlying causes. Hoffmann and coworkers,25 in a pop-
lation of black HIV-infected patients from the Durban
troke Data Bank, free of drug abuse and opportunistic in-
ections, compared with age- and sex-matched controls,
ound no significant overall increased of stroke rate among
IV stroke patients (16%). However, there was a higher rate








































































42 A. Nogueira Pinto91% among cases and 36% among controls). The authors
uggested that the presence of a coexistent prothrombotic
tate could have been responsible for this finding. Evidence
f a direct effect of HIV infection or immunosuppression on
he risk of stroke was not found.
It is important to note that, except for the Evers and co-
orkers’ study,28 all of the others were conducted before the
ntroduction of protease inhibitors (PIs) and subsequent anti-
etroviral combination drug regimens (HAART). This new
herapy, leading to a lengthening of the disease-free survival,
reated an older population that is at higher risk for stroke. In
ddition, recent evidence suggests that a potential risk of
ccelerated atherosclerosis that may accompany dyslipide-
ia and insulin resistance is more frequent among patients in
he HAART regimen, which could lead to a higher risk for
troke in the AIDS population.34
utopsy Series
ccording to Pinto’s review paper,2 the proportion of AIDS
ases with findings of cerebrovascular disease (CVD) on neu-
opathological examinations was much higher than in clini-
al series, with a 39% of CVD findings (98 among 251 pa-
ients), and a prevalence rate from 4 to 34%.16,35-44 A higher
atio of ischemic to hemorrhagic cases was observed (72
mong 98 patients with IS [73%] and 12 among 98 with ICH
12%]). As in the clinical series, the majority of patients were
omosexual men or IVDA. These autopsy findings were not
ssociated with acute CVD before death and the majority of
tudies do not distinguish between asymptomatic findings or
hose with a history of IS. More recently the Edinburgh HIV
utopsy cohort45 described the neuropathological findings
mong HIV patients with a full neuropathological postmor-
em examination, after excluding patients with CNS pathol-
gy or normal brain. Out of 183 patients, of whom 44 (24%)
ere pre-AIDS patients, 26 were included; in 10 of those IS
as observed (5.5% of the overall population; 7% of the
IDS patients). All were advanced AIDS cases who died be-
ore the HAART regimen was introduced. Only one patient
ad a TIA and another had an asymptomatic basal ganglia
nfarct on CT scan. All others were asymptomatic for CVD.
ll cases had multiple ischemic infarcts on neuropatho-
ogical examination, and a nonvasculitic vasculopathy was
ound, yet it was not associated with virus load. The au-
hors concluded that cerebral infarcts in HIV-infected pa-
ients are not common in the absence of CNS opportunis-
ic infection, lymphoma, or embolic sources. Each of those
nderlying conditions leading to stroke should be ex-
luded before assuming that the cause is HIV itself—as a
esult of a vasculopathy or some other yet unrecognized
athogenic mechanism. Previous series have also de-
cribed a mural thickening of small vessels in half the
atients and multiple subclinical infarcts.42 A vasculopa-
hy mediated primarily by HIV was thought to be respon-
ible for 40% of IS in another autopsy study.16 cschemic Stroke in
IV-Infected Patients
s previously reported in clinical, radiological, and patholog-
cal series, there is an increased risk of IS in AIDS patients.
here are several potential causes for IS in HIV-infected pa-
ients (Table 1).3 Data are not available to determine whether
isk factors for HIV infection influence the etiology and fre-
uency of CVD. The most frequently reported causes are
ardioembolism or opportunistic diseases of the CNS,2,8-12,44
ollowed by hemostatic abnormalities, especially protein S
eficiency.21,27 Ischemic strokes in IVDA have been rarely
eported, except when associated with endocarditis.2,44
ther possibilities were vasculitis, vasospasm, or foreign
ody embolism. Therefore, a higher rate of stroke was to be
xpected in HIV-infected/AIDS patients with an actual his-
ory of IVDA compared with the age-matched sample from
he general population. Ischemic stroke has been classified as
able 1 Potential Causes of Ischemic Stroke in AIDS/HIV-
nfected Patients
Cardioembolic
Nonbacterial thrombotic endocarditis (with and without
IVDA)
Infective endocarditis (IVDA)




























Impaired vascular bed-specific homeostasis
Accelerated atherosclerosis with protease inhibitors
Dyslipidemia, insulin resistance
Endothelial dysfunction








































































































AIDS/HIV infection and cerebrovascular disease 43he use of PIs has been associated with an increased risk of
ascular events including stroke.26
Cardiac disease is frequent in HIV-infected/AIDS patients
nd usually has been reported as the principal cause of em-
olic stroke. The most common cardiac lesions are nonbac-
erial thrombotic endocarditis and infectious endocarditis,
oth associated or not with IVDA. Dilated myocardiopathy,
ural thrombi, myxomatous degeneration of valves, and
IV myocarditis have also been described.
Several opportunistic infections have been associated with
troke in HIV-infected/AIDS patients (Table 1). These causes
re usually present in the advanced stage of the disease and
hus with the introduction of prophylactic therapy for oppor-
unistic infections and the current use of HAART regimen;
heir incidence will probably decrease dramatically, although
hus far no data exist to confirm this assumption.
A variety of hemostatic abnormalities has been reported in
IV-infected patients with IS. The most consistently de-
cribed prothrombotic state has been protein S deficiency,
ut antiphospholipid antibodies had also been found.11 A
isseminated intravascular coagulation can cause IS in termi-
ally ill patients due to dehydration.39,44 An unrecognized
rothrombotic state has been suspected responsible for the
igh incidence of “cryptogenic strokes,” but no data sup-
orted this evidence.46 Other forms of hypercoagulability
ave been seen in HIV patients, but no data exist to confirm
hat their frequency is higher than in the general popula-
ion.46
As previously discussed, IVDA has been rarely associated
ith IS in HIV-infected/AIDS patients, even though the active
se of cocaine and heroin increase the risk of stroke.While in
eroin users stroke usually occurred after reintroduction of
he drug, suggesting an immunological mechanism, in co-
aine users the mechanism of ischemia is unclear.47
As a result of recent clinical series, an HIV-related vascu-
opathy has been recently suggested as the mechanism of
troke in HIV/AIDS patients who are free of other risk factors
or these vascular changes. A case of recurrent stroke in HIV
atients with isolated central nervous system angiitis in the
bsence of an opportunistic cause had been described.48
hose findings were already reported in autopsy series and
he most relevant data are provided by the Edinburgh Au-
opsy Cohort Study,45 where the presence of an asymptom-
tic vasculopathy characterized by small-vessels wall thick-
ning, perivascular space dilation, rarefaction, and pigment
eposition with vessel wall mineralization, and occasional
erivascular inflammatory cells infiltrates, was found, with-
ut definitive evidence of vasculitis. These vascular changes
ere similar to those found in elderly patients with vascular
isk factors and cerebral atherosclerosis, although the Edin-
urgh cases were young patients, free of vascular risk factors.
e should not forget, however, that all autopsy findings were
ot associated with acute CVD. Abnormalities of cerebral
erfusion have been documented in asymptomatic HIV pa-
ients using 113Xe single-photon emission computed tomog-
aphy49 and confirmed in a transcranial Doppler study when
educed baseline blood flow velocity was found after acet-
zolamide injection when compared with controls, suggest- ang alterations of cerebral resistance at the arteriolar level.50
hose findings suggest that a CNS vasculopathy is present in
IV-infected patients without symptoms of cerebrovascular
isease and that the disorder is confined to small cerebral
rterioles or at least to the peripheral vascular bed, the same
essels showing pathological changes in the autopsy series
iscussed above. This vasculopathy could be due to direct
nfection of the vessel walls by HIV.45 However, the clinical
elevance of HIV-related vasculopathy is still a matter of de-
ate.
Figure 1 illustrates the MRI findings of a 59-year-old male





he causes for ICH in HIV-infected patients are listed in
able 2.2,6-8,23 The mortality tends to be higher and ICH is a
ater complication of HIV infection, generally with CD4
-lymphocytes cells below 200 mm3.23 From previous stud-
es it was unclear whether hemorrhagic stroke was more fre-
uent in the HIV-infected population,2,21 although some au-
hors have suggested that this was the case,23 with a 1%
ncidence, higher than expected in young adults. Cole and
oworkers29 in the first population case-based study found an
ncidence of 0.11% per year for ICH with an adjusted RR of
2.7% (95% CI, 4 to 40), confirming that AIDS is strongly
ssociated with ICH. This incidence may decline with the
AART regimen and the subsequent decrease in the princi-
al conditions conferring an increased risk of ICH.
AART Regimen and
IV-Infected/AIDS Patients
linical atherosclerotic disease was not frequently re-
orted in HIV-infected/AIDS patients in the pre-PIs era,
lthough this low incidence of atherosclerosis may have
een related to the reduced live expectancy.51 With the
ntroduction of PIs and HAART regimen, a clear reduction
f comorbid conditions, including opportunistic infec-
ions, and premature mortality occurred. This could ac-
ount for a growing prevalence of atherosclerosis in HIV-
nfected patients as they get older and as underlying pro-
therosclerotic effects of the HIV infection itself become
vident.52-54
Though inconclusive at this time, data have suggested that
AART regimen is associated with an increased incidence of
etabolic changes—dyslipidemia, insulin resistance—and
omatic—lipodystrophy/lipoatrophy—compared with the
eneral population, which is associated with an increased
isk of cardiovascular disease, mainly coronary artery disease
nd stroke.34 Treatment with PIs has been associated with
evere premature atherosclerotic vascular disease, albeit
ostly on the basis of anecdotal evidence.55-58 Marked lipid
















































44 A. Nogueira Pintoith PIs55,59,60 and the largest published study has shown an
verage increase in the total cholesterol and serum triglycer-
de levels of 28 and 96%, respectively, when compared with
retreatment levels and matched PI-naïve HIV-infected con-
rols.51
Myocardial infarction has been the most frequent vas-
ular event, but stroke also can occur.26 Studies published
efore HAART therapy showed that subclinical echocar-
iographic abnormalities independently predict adverse
utcomes and identify high-risk groups to target for early
ntervention or therapy.61 However, contrasting opinion
till exists about the incidence of coronary artery disease
mong HIV-infected patients receiving PIs including
AART.62,63 Nevertheless for HIV patients on HAART reg-
men it may be important to evaluate traditional cardio-
ascular risk factors and to try to intervene in those that
an be modified.34
Figure 1 A 59-year-old man, without known vascular and
of left hemiparesis. Diagnostic work-up revealed HIV1
MRI showed multiple ischemic lesions (axial diffusion,











VascularfMycotic aneurysm (IVDA)Whether any particular PI drug or a combination of PI
gents is more atherogenic remains unclear and, although
tudies have preferentially implicated different PIs (most
requently ritonavir), all available PIs induced potentially
therogenic metabolic derangements.60,64,65 However,
hile the association between PIs and dyslipidemia is well
efined, the risk of clinically relevant premature athero-
clerosis remains to be established.65 Fibric acid deriva-
ives and statins can lower HAART-associated increases in
yslipidemia, although further data are needed on inter-
ctions between statins and PIs, as most statins are metab-
lized through the CYP3A4 pathway, inhibited by PIs. The
tatin that is least influenced by the CYP3A4 pathway is
ravastatin.34 Compared with the general population,
IV-infected patients receiving HAART regimens are at
igher risk of developing hypertension. Calcium channel
lockers and ACE inhibitors are the preferred therapy,
lthough controlled clinical trials are lacking.34 Moreover,
IV-infected patients, especially those with fat redistribu-
ion, may develop coagulation abnormalities, eg, in-
reased levels of fibrinogen, plasminogen activator inhib-
tor-1, and tissue-type plasminogen activator antigen, and
rotein S deficiency.66 Thrombocytosis following HAART
herapy may also contribute to cardiovascular disease.67
We can conclude that some HAART regimens may pro-
ote a process of accelerated atherosclerosis, possibly asso-
iated with dyslipidemia and insulin resistance, and an in-
reased risk of death by myocardial infarct and stroke. A
areful laboratory and cardiac screening is warranted, espe-
ially in patients with underlying cardiovascular disease risk
isk factors, was admitted to the hospital for acute onset
IDS disease criteria were found to be present. His brain































































AIDS/HIV infection and cerebrovascular disease 45onclusions
here is now clear evidence that stroke (IS and ICH) is
trongly associated with AIDS. However, population-based
tudies with HIV-infected patients without AIDS criteria are
acking. The most common causes for IS are cardioembolism
nd opportunistic infections, although in recent series a large
umber of cryptogenic strokes were found, probably related
o HIV vasculopathy. This entity is confined to small cerebral
essels and is probably due to direct HIV infection of the
essel walls. In black populations series, the most frequent
troke etiologies are meningitis and proteins S deficiency, so
oth these causes should be excluded. ICH is usually due to
pportunistic neoplasm or infection and thrombocytopenia
nd is less frequent than IS. The introduction of HAART
egimen had led to reduced morbidity and mortality of those
nfected with HIV. Although the association between PIs and
yslipidemia is well defined, the risk of clinically relevant
remature atherosclerosis remains to be established.
The relationship of HIV infection and stroke is undergoing
emarkable changes, as the prognosis of HIV infection is
hanging with an increased survival rate of patients, immune
estoration in HAART-treated patients, and lower incidence
ates of opportunistic infections. However metabolic effects
f the drugs used for treatment and older age with underlying
raditional risk factorsmight lead to an increased incidence of
schemic strokes, due to possible accelerated atherosclerosis
n patients treated with HAART. Furthermore, HIV-related
asculopathy, more frequent in recent series, should not be
orgotten, yet its clinical relevance is still to be established.
pidemiological studies should be performed on aging HIV
opulations to state the impact of these new data on the
ncidence of cardiovascular diseases and stroke predomi-
antly in HIV-infected patients.
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